Targets › EPAS1
2 programs from 2 companies in 26 trials: 11 Phase 2, 8 Phase 3, 6 Phase 1, 1 Phase 4; Oncology; next expected readout Nov 2026.
Transcription factor involved in the induction of oxygen regulated genes. Heterodimerizes with ARNT; heterodimer binds to core DNA sequence 5'-TACGTG-3' within the hypoxia response element (HRE) of target gene promoters (By similarity). (UniProt, Q99814)
Open in Phaseline: the race on EPAS1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Merck & Co. (MSD) | Belzutifan (MK-6482) Endothelial PAS domain-containing protein 1 inhibitor | EPAS1 | Phase 3 | Carcinoma, Renal Cell; Renal Cell Carcinoma; Von Hippel-Lindau Disease; Neoplasm Malignant … | Dec 2026 |
| Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Belzutifan (PT2977) Endothelial PAS domain-containing protein 1 inhibitor | EPAS1 | Phase 2 | Renal Cell Carcinoma (RCC); VHL - Von Hippel-Lindau Syndrome; Advanced Solid Tumors; ccRCC | Nov 2026 |
Carcinoma, Renal Cell (6) Renal Cell Carcinoma (4) Pheochromocytoma and Paraganglioma (PPGL) (2) Von Hippel-Lindau Disease (1) Neoplasm Malignant (1) Metastatic Breast Cancer (1) Pheochromocytoma/Paraganglioma (1) Malignant Neoplasm (1) Metastatic Castration-Resistant Prostate Cancer (1) Ovarian Cancer (1) Clear Cell Renal Cell Carcinoma (1) Active Surveillance (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.